Senores’ FY27 Guidance: 29–31% EBITDA, Apnar Ramp

Senores Pharmaceuticals Limited — Q4 FY26 Earnings Call (May 14, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “robust performance,” “strong execution,” “remain optimistic,” “confidence,” and “robust product pipeline”.
• They provide quantitative FY27 guidance (revenue and PAT growth) and frame FY26 as “surpass[ing] guidance.”
• Some conservatism appears in guidance language (“minimum,” “moving parts,” “uncertain environment”), but overall tone is still bullish.

2. Key Themes from Management Commentary

• Strong FY26 delivery and credibility:
• “62% revenue growth and 108% PAT growth” vs FY25; “surpass[es] our guidance.”
• Regulated market momentum (US-led):
• Regulated market revenue grew 83% Y-o-Y in FY26.
• ANDA expansion: 51 approved ANDAs (up from 22 in March ’25); 20 launched, 30 more expected in coming quarters.
• Mentions spot business as consistent and not expected to grow.
• Emerging markets turning profitable and improving margins:
• Emerging market revenue +20% in FY26.
• EBITDA margin improved to low-to-mid double digits; cash flow positive.
• PIC/S approval for emerging market facility expected by June/July 2026.
• CDMO/CMO as operating leverage + end-to-end capability:
• Emphasis on end-to-end regulatory/manufacturing support and that CMO/CDMO helps absorb operating costs and drive leverage.
• US expansion via acquisitions/JVs:
• Acquired 75% stake in Apnar Pharma in Q4FY26; remaining 25% expected by year-end.
• Zoraya Pharmaceuticals step-down subsidiary (US commercialization/distribution).
• Amerisyn JV for US government procurement/FSS tenders.
• India branded generics scaling:
• FY26 branded generic revenue ~INR40 cr, nearly 5x YoY.
• Field force expansion and hospital supplies for visibility.
• Cash flow focus despite growth:
• Operating cash flow improving; working capital conversion improving “meaningfully.”

3. Q&A Analysis

Theme A: Regulated market composition, spot business, and working capital

• Core questions
• How has the sourced/spot business evolved and what % of revenue is it?
• Why did working capital days jump (114 → 187 days)?
• Expected steady-state for Apnar’s working capital/receivables.
• Management response
• Spot business is “usually the spot business,” consistent, and no further growth expected; 10–12% of total revenue.
• Working capital jump attributed to Apnar acquisition: “inflated our working capital” because sales weren’t yet coming through.
• Excluding Apnar, net working capital cycle ~104 days.
• Apnar sales expected from next year (FY26-27); “at par with our current operating cycle.”
• Assessment
• Mostly direct answers; however, timing of working capital normalization is somewhat dependent on Apnar ramp (“sales coming in from next year”).

Theme B: ANDA launch mix (CGT vs non-CGT) and margin outlook

• Core questions
• Of the 30 ANDA launches, how many are CGT products?
• What EBITDA margin should be expected going forward (FY27+), given current ~26.5%?
• Management response
• CGT count: “difficult to demonstrate right now,” but “quite a bit” qualify; will share later.
• Margin: guided 29%–31% EBITDA; current margin suppressed by Apnar expenses without corresponding revenue yet.
• Apnar expected to contribute INR80–100 cr revenue in FY27; shipments ramping from April onwards.
• Assessment
• Partial/evasive on CGT count (“difficult… right now”).
• Margin explanation is plausible but relies on Apnar revenue ramp to normalize.

Theme C: Emerging markets margin trajectory and facility approvals

• Core questions
• What are optimal emerging market margins over 3–4 years?
• How much of margin improvement is operational vs forex?
• Timeline for PIC/S approval and impact.
• Management response
• Emerging market EBITDA margin expected to sustain 18–19%, potentially 20–21% next year; further improvement after crossing INR220–250 cr revenue.
• Forex contribution: improvement mainly due to product change; forex effect about INR ~3 cr.
• PIC/S approval expected by June/July 2026 to expand footprint (South Africa, Vietnam, etc.).
• Assessment
• Stronger quantification on forex impact (~INR3 cr), but still qualitative on exact drivers of margin step-ups.

Theme D: Apnar ramp, revenue/EBITDA, and market opportunity

• Core questions
• Revenue and EBITDA expectations from Apnar over 2–3 years.
• What drives Apnar growth and what is the market size opportunity?
• Management response
• FY26 quarter revenue modest; FY27 quarter revenue INR10–20 cr; steady-state full year INR80–100 cr.
• 2–3 years: INR180–200 cr revenue visible (requires expansion).
• Market opportunity framed as US business console; accessible market for approved products ~$1B; company aspires to INR2,500–3,000 cr US revenue in 3–4 years.
• Assessment
• Clear numbers on Apnar revenue; but “market size” is aggregated into broader US strategy (less precise for Apnar specifically).

Theme E: Balance sheet / accounting items

• Core questions
• Meaning of “other financial assets” increasing (INR116 → INR172 cr).
• Is it unbilled revenue/royalty?
• Management response
• Explained as profit share booked under Ind AS but “parked as a financial asset till it is realized.”
• Timing typically 1–2 months up to max six months.
• Assessment
• Answer is detailed and consistent; however, they suggest it will “plateau” later—still dependent on launch cadence.

Theme F: Capex, tax rate normalization, and cash flow/FCF

• Core questions
• Capex incurred FY26 and planned FY27.
• Normalized tax rate.
• When FCF/FCF-positive year might occur.
• Management response
• Capex FY26: ~INR230 cr (includes ~INR65 cr ANDA acquisition).
• Capex FY27: ~INR200 cr.
• Tax rate: FY26 jump due to US + India taxation; normalized ~23% average.
• FCF: expects free cash flow in FY26–FY27 (based on IPO funds availability and capex plan).
• Assessment
• Generally direct; FCF timing is still conditional (“should generate”).

Theme G: US JV (Amerisyn) margin expectations

• Core questions
• Incremental PAT margin from JV; are margins thin for government procurement?
• Management response
• They claim margins are not very thin; JV revenue budget INR80–100 cr (conservatively INR50–70 cr) and profitability “almost an average of US EBITDA business… upwards of ~40%.”
• Assessment
• Potentially aggressive margin claim for government procurement; management ties it to “different vertical” and overall US EBITDA framework.

4. Guidance / Outlook

Explicit Guidance (quantitative)

• FY27 outlook (consolidated):
• Revenue growth: ~30% to 40%
• PAT growth: ~50% to 60%
• EBITDA blended margin (FY27):
• 29% to 31% (management says they “would not want to change” this EBITDA guidance)
• Apnar revenue:
• FY27: INR80–100 cr (also stated as “budgeted”)
• 2–3 years: INR180–200 cr
• Emerging markets:
• FY27 emerging market revenue: INR180 cr
• Emerging market EBITDA margin: 18–19%, potentially 20–21% next year; further improvement after INR220–250 cr revenue
• Capex:
• FY26 capex: ~INR230 cr
• FY27 capex: ~INR200 cr
• Tax rate normalization:
• Normalized average tax rate: ~23%
• ANDA rollout:
• Remaining approved ANDAs: complete rollout in next 6–8 quarters
• By ~6–8 quarters: 90–95% of 51 commercialized

Implicit Signals (qualitative)

• Management repeatedly frames FY27 guidance as “minimum” due to “moving parts” and external uncertainty (shipping lines, inflationary pressures, macro/geopolitics).
• They indicate potential upside if macro/geopolitics improve (“can further improve” margins).
• They emphasize visibility from order pipeline and upcoming product launches.

5. Standout Statements (direct / high-signal)

• FY26 performance vs guidance:
• “This clearly surpasses our guidance for the year.”
• FY27 confidence:
• “For FY27, our initial outlook indicates revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60%.”
• ANDA scale-up:
• “approved ANDAs… more than doubled, increasing from 22 ANDAs in March ’25 to 51 in March ’26”
• “additional 30 approved ANDAs… will be launched over the next few quarters”
• Working capital explanation:
• “working capital has shown that jump… while sales have not come in from Apnar”
• Margin normalization logic:
• “margins have come in around 26.5%… suppressed because of the acquisition of Apnar where we’ve incurred the expenses… but the subsequent revenue has not come in”
• Emerging market margin path:
• “margin will sustain at 18%, 19%… maybe add another 100–200 bps… settle at about 20%, 21%”
• Apnar ramp numbers:
• “steady-state… INR80 crores to INR100 crores” and “INR180 crores to INR200 crores in two to three years”
• US JV margin claim:
• “Profitability… almost an average of what our US EBITDA business is… upwards to about 40%.”
• FCF expectation:
• “we should generate free cash flow in FY’26, ’27.”

6. Red Flags / Positive Signals

Red Flags
– CGT launch mix not quantified: “difficult to demonstrate right now” for CGT count—limits investor ability to assess margin durability.
– Margin claims depend on ramp timing: multiple answers tie margin normalization to Apnar revenue starting April / next year.
– Potentially aggressive JV margin assumption for government procurement (Amerisyn) vs typical “thin margin” expectations—management disputes “thin,” but provides limited substantiation.
– Working capital normalization is conditional on Apnar sales ramp; current cycle inflated by acquisition timing.

Positive Signals
– Clear, numeric guidance for FY27 revenue/PAT and EBITDA margin.
– Operational explanations for accounting items (other financial assets) and working capital.
– Emerging markets cash flow positive and margin improvement narrative supported by quantified forex impact (~INR3 cr).
– ANDA rollout timeline (6–8 quarters) and commercialization progress (20 launched already).

7. Historical Comparison & Consistency Analysis (vs prior 3–4 calls)

a. Change in Tone Over Time

• Q1FY26 (Jul 2025): optimistic but more about structural advancement; emerging market margin guided 15–17% sustainable.
• Q2/H1FY26 (Nov 2025): still confident; emerging market margin discussed as low single digits then improving; emphasized visibility and cautious targets.
• Q3FY26 (Jan 2026): confidence maintained; guided FY26 targets and highlighted Apnar acquisition (75% stake) as growth driver; emerging market cash flow positive and margin improving to mid-teens.
• Q4FY26 (May 2026): tone becomes more assertive with strong FY26 outperformance and specific FY27 quantitative guidance (30–40% revenue, 50–60% PAT).
• Classification: More Optimistic than earlier calls.
• Shift: from “on track / confident” to “surpass guidance” and more granular FY27 targets.

b. Tracking Past Commitments vs Outcomes

• Apnar-related working capital / ramp
• Prior (Q3FY26 Jan 2026): Apnar expected to be cash-flow positive and revenue INR120–150 cr in FY27 (and “very early” to quantify margin expansion).
• Current (Q4FY26 May 2026): FY27 Apnar revenue revised to INR80–100 cr (lower than earlier INR120–150 cr).
• Flag: ⏳ Delayed / Reduced expectation (at least on revenue number).
• Emerging market margin
• Prior (Q2/H1FY26 Nov 2025): emerging market EBITDA margin guided mid-teens over 2–3 years; also earlier references to double-digit trajectory.
• Current: emerging market EBITDA margin now low-to-mid double digits, cash flow positive; FY27 margin path 18–21%.
• Flag: ✅ Delivered / Improved (directionally consistent with improvement).
• ANDA rollout cadence
• Prior (Q3FY26 Jan 2026): 46 approved ANDAs by Dec 2025; 28 approved ANDAs for launch; rollout in next quarters.
• Current: 51 approved ANDAs by March 2026; complete rollout in 6–8 quarters and 90–95% commercialized.
• Flag: ✅ On track / Accelerated (portfolio growth continued).

c. Narrative Shifts

• From “capacity expansion” to “acquisition-driven ramp”:
• Earlier calls emphasized US line expansions and sterile facility timing.
• Current call heavily emphasizes Apnar acquisition, Amerisyn JV, and US commercialization via Zoraya.
• Emerging markets story becomes profitability-forward:
• Earlier: emerging markets were struggling (single-digit EBITDA margin).
• Now: “cash flow positive,” margin stabilization guidance, and facility approvals (PIC/S) for expansion.
• Margin explanation increasingly tied to acquisition timing:
• Current call explicitly attributes blended margin suppression to Apnar expenses without revenue yet.

d. Consistency & Credibility Signals

• Medium credibility (improving but with some slippage):
• Strength: management provides explanations for accounting/working capital and ties guidance to pipeline.
• Weakness: some numbers shift (e.g., Apnar FY27 revenue expectation reduced from INR120–150 cr to INR80–100 cr).
• CGT quantification remains non-specific, reducing transparency.

e. Evolution of Key Themes

• Demand / pipeline: Improving and expanding (ANDA approvals doubling; rollout timeline reiterated).
• Margins: Upward trajectory; emerging markets moved from low single digits to double digits; regulated margins guided to sustain high levels.
• Expansion strategy: Shift toward US commercialization + acquisitions; sterile facility expansion timing becomes more conditional (“pushed” fourth line due to Apnar).
• Cash flow: Consistently emphasized; now includes explicit FCF expectation.

f. Additional Insights (cross-period intelligence)

• A quiet risk build appears around ramp timing and working capital: Apnar acquisition repeatedly impacts working capital and margin timing, implying execution/ramp risk is material even if growth guidance remains intact.
• Management’s confidence is high, but specificity decreases on certain margin drivers (CGT count), suggesting they may be managing investor expectations around the most margin-sensitive variables.